For the year ending 2025-12-31, PLX had -$5,080K decrease in cash & cash equivalents over the period. -$13,631K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -6,604 |
| Share-based compensation | 2,297 |
| Depreciation | 1,465 |
| Financial (income) expenses, net | -606 |
| Changes in accrued liability for employee rights upon retirement | 22 |
| Changes in deferred income tax asset | 340 |
| Gain on amounts funded in respect of employee rights upon retirement | 20 |
| Loss (gain) on sale of fixed assets | 0 |
| Gain on conversions of convertible notes | 0 |
| Amortization of debt issuance costs and debt discount | 0 |
| Decrease in contracts liability | 0 |
| Decrease (increase) in accounts receivable-trade and other assets | 5,890 |
| Changes in operating lease right of use assets, net | 15 |
| Increase in inventories | 4,486 |
| Increase in accounts payable and accruals | 292 |
| Net cash provided by (used in) operating activities | -11,993 |
| Investment in bank deposits | 5,000 |
| Short-term deposit withdrawal | 5,000 |
| Purchase of property and equipment | 1,638 |
| Proceeds from sale of property and equipment | 0 |
| Amounts paid (funded) in respect of employee rights upon retirement, net | 26 |
| Increase in restricted deposit | 702 |
| Net cash provided by (used in) investing activities | -2,366 |
| Payment for convertible notes redemption | 0 |
| Proceeds from issuance of common stock under the sales agreement, net | 6,812 |
| Exercise of warrants and options | 2,514 |
| Net cash provided by (used in) financing activities | 9,326 |
| Effect of exchange rate changes on cash and cash equivalents | -47 |
| Net increase (decrease) in cash and cash equivalents | -5,080 |
| Balance of cash and cash equivalents at beginning of year | 19,760 |
| Balance of cash and cash equivalents at end of year | 14,680 |
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)